Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical (LFCR) Asset Writedowns and Impairment: 2016-2024

Historic Asset Writedowns and Impairment for Lifecore Biomedical (LFCR) over the last 2 years, with May 2024 value amounting to -$1.4 million.

  • Lifecore Biomedical's Asset Writedowns and Impairment fell 240.20% to -$1.4 million in Q2 2024 from the same period last year, while for Feb 2024 it was $47.5 million, marking a year-over-year decrease of 38.44%. This contributed to the annual value of $1.3 million for FY2023, which is 98.34% down from last year.
  • According to the latest figures from Q2 2024, Lifecore Biomedical's Asset Writedowns and Impairment is -$1.4 million, which was down 200.00% from $1.4 million recorded in Q1 2024.
  • In the past 5 years, Lifecore Biomedical's Asset Writedowns and Impairment registered a high of $46.1 million during Q2 2022, and its lowest value of -$1.4 million during Q2 2024.
  • Moreover, its 3-year median value for Asset Writedowns and Impairment was $1.0 million (2023), whereas its average is $9.2 million.
  • Per our database at Business Quant, Lifecore Biomedical's Asset Writedowns and Impairment spiked by 47,656.72% in 2021 and then crashed by 240.20% in 2024.
  • Quarterly analysis of 5 years shows Lifecore Biomedical's Asset Writedowns and Impairment stood at $67,000 in 2020, then soared by 47,656.72% to $32.0 million in 2021, then surged by 16,328.52% to $46.1 million in 2022, then plummeted by 97.83% to $1.0 million in 2023, then slumped by 240.20% to -$1.4 million in 2024.
  • Its Asset Writedowns and Impairment was -$1.4 million in Q2 2024, compared to $1.4 million in Q1 2024 and $1.0 million in Q2 2023.